Singapore-based Biotherapeutics Startup Hummingbird Bioscience Secures US$19 Million in Mirae Asset Venture Investment-led Series B Funding Round
Singapore-based healthtech startup Hummingbird Bioscience had successfully secured US$19 million in a funding round co-led by Mirae Asset Venture Investment, a South Korea-based venture capital firm specializing in buyout, growth, incubation and cross-border investments, and GNTech Venture Capital, which is the corporate venture investment arm of Kooksoondang Brewery that has…Continue Reading